XML 34 R25.htm IDEA: XBRL DOCUMENT v2.4.0.8
Stockholders' Equity (Tables)
9 Months Ended
Sep. 30, 2013
Equity [Abstract]  
Summary of Restricted Stock Unit Activity

The following table summarizes RSU activity for the nine months ended September 30, 2013:

 

           Weighted         
           Average
Grant-
        
     Number of     Date Fair      Aggregate  
     Units     Value      Intrinsic Value  

Units outstanding, beginning of period

     582,212      $ 5.42      

Granted

     736,479        8.98      

Released

     (158,700     5.39      

Forfeited

     (44,814     7.24      
  

 

 

      

Units outstanding, end of period

     1,115,177        7.71       $ 16,593,834   
  

 

 

      
Summary of the Company's Stock Options

The following table summarizes stock option activity for the nine months ended September 30, 2013:

 

                  Average         
           Weighted      Remaining         
     Number of     Average      Contractual      Aggregate  
     options     Exercise Price      Life (years)      Intrinsic Value  

Options outstanding, beginning of period

     6,321,076      $ 6.05         

Granted

     —             

Exercised

     (1,985,596     5.14         

Expired / forfeited

     (132,288     5.72         
  

 

 

         

Options outstanding,end of period

     4,203,192        6.49         4.51       $ 35,702,302   
  

 

 

         

Exercisable at September 30, 2013

     3,754,714        6.71         4.31         31,097,408   
  

 

 

         

Expected to vest after September 30, 2013

     380,339        4.60         6.19         3,908,919   
  

 

 

         
Reported Share-Based Compensation

Share-based compensation was classified as follows:

 

     Three Months Ended
September 30,
     Nine Months Ended
September 30,
 
     2013      2012      2013      2012  

Cost of products sold

   $ 49,632       $ 38,085       $ 133,500       $ 133,977   

Sales, general and administrative expenses

     735,433         657,870         2,292,672         1,631,234   

Research and development expenses

     177,929         153,433         479,463         431,839   
  

 

 

    

 

 

    

 

 

    

 

 

 

Total share-based compensation

   $ 962,994       $ 849,388       $ 2,905,635       $ 2,197,050